1
|
Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 2015; 47:1187-93. [PMID: 26301494 DOI: 10.1038/ng.3389] [Citation(s) in RCA: 341] [Impact Index Per Article: 37.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 07/31/2015] [Indexed: 11/09/2022]
Abstract
Hepatocellular carcinomas (HCCs) are liver tumors related to various etiologies, including alcohol intake and infection with hepatitis B (HBV) or C (HCV) virus. Additional risk factors remain to be identified, particularly in patients who develop HCC without cirrhosis. We found clonal integration of adeno-associated virus type 2 (AAV2) in 11 of 193 HCCs. These AAV2 integrations occurred in known cancer driver genes, namely CCNA2 (cyclin A2; four cases), TERT (telomerase reverse transcriptase; one case), CCNE1 (cyclin E1; three cases), TNFSF10 (tumor necrosis factor superfamily member 10; two cases) and KMT2B (lysine-specific methyltransferase 2B; one case), leading to overexpression of the target genes. Tumors with viral integration mainly developed in non-cirrhotic liver (9 of 11 cases) and without known risk factors (6 of 11 cases), suggesting a pathogenic role for AAV2 in these patients. In conclusion, AAV2 is a DNA virus associated with oncogenic insertional mutagenesis in human HCC.
Collapse
Affiliation(s)
- Jean-Charles Nault
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris-Seine Saint-Denis, Site Jean Verdier, Pôle d'Activité Cancérologique Spécialisée, Service d'Hépatologie, Bondy, France
| | - Shalini Datta
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France
| | - Sandrine Imbeaud
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France
| | - Andrea Franconi
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France
| | - Maxime Mallet
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France
| | - Gabrielle Couchy
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France
| | - Eric Letouzé
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France
| | - Camilla Pilati
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France
| | - Benjamin Verret
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France
| | - Jean-Frédéric Blanc
- Centre Hospitalier Universitaire (CHU) de Bordeaux, Department of Hepatology, Hôpital Saint-André, Bordeaux, France.,INSERM, UMR 1053, Bordeaux, France.,Université de Bordeaux, Bordeaux, France
| | - Charles Balabaud
- INSERM, UMR 1053, Bordeaux, France.,Université de Bordeaux, Bordeaux, France
| | - Julien Calderaro
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France.,AP-HP, Department of Pathology, CHU Henri Mondor, Créteil, France
| | - Alexis Laurent
- AP-HP, Department of Digestive and Hepatobiliary Surgery, CHU Henri Mondor, Créteil, France.,INSERM, U955, Créteil, France
| | | | - Paulette Bioulac-Sage
- INSERM, UMR 1053, Bordeaux, France.,Université de Bordeaux, Bordeaux, France.,CHU de Bordeaux, Pellegrin Hospital, Department of Pathology, Bordeaux, France
| | - Fabien Calvo
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France.,Institut Gustave Roussy, Core Europe, Villejuif, France
| | - Jessica Zucman-Rossi
- INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France.,Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France.,Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France.,AP-HP, Hôpital Européen Georges Pompidou, Paris, France
| |
Collapse
|
2
|
Millet R, Jolinon N, Nguyen XN, Berger G, Cimarelli A, Greco A, Bertrand P, Odenthal M, Büning H, Salvetti A. Impact of the MRN Complex on Adeno-Associated Virus Integration and Replication during Coinfection with Herpes Simplex Virus 1. J Virol 2015; 89:6824-34. [PMID: 25903339 PMCID: PMC4468484 DOI: 10.1128/jvi.00171-15] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 04/13/2015] [Indexed: 12/11/2022] Open
Abstract
UNLABELLED Adeno-associated virus (AAV) is a helper-dependent parvovirus that requires coinfection with adenovirus (AdV) or herpes simplex virus 1 (HSV-1) to replicate. In the absence of the helper virus, AAV can persist in an episomal or integrated form. Previous studies have analyzed the DNA damage response (DDR) induced upon AAV replication to understand how it controls AAV replication. In particular, it was shown that the Mre11-Rad50-Nbs1 (MRN) complex, a major player of the DDR induced by double-stranded DNA breaks and stalled replication forks, could negatively regulate AdV and AAV replication during coinfection. In contrast, MRN favors HSV-1 replication and is recruited to AAV replication compartments that are induced in the presence of HSV-1. In this study, we examined the role of MRN during AAV replication induced by HSV-1. Our results indicated that knockdown of MRN significantly reduced AAV DNA replication after coinfection with wild-type (wt) HSV-1 or HSV-1 with the polymerase deleted. This effect was specific to wt AAV, since it did not occur with recombinant AAV vectors. Positive regulation of AAV replication by MRN was dependent on its DNA tethering activity but did not require its nuclease activities. Importantly, knockdown of MRN also negatively regulated AAV integration within the human AAVS1 site, both in the presence and in the absence of HSV-1. Altogether, this work identifies a new function of MRN during integration of the AAV genome and demonstrates that this DNA repair complex positively regulates AAV replication in the presence of HSV-1. IMPORTANCE Viral DNA genomes trigger a DNA damage response (DDR), which can be either detrimental or beneficial for virus replication. Adeno-associated virus (AAV) is a defective parvovirus that requires the help of an unrelated virus such as adenovirus (AdV) or herpes simplex virus 1 (HSV-1) for productive replication. Previous studies have demonstrated that the cellular Mre11-Rad50-Nbs1 (MRN) complex, a sensor and regulator of the DDR, negatively regulates AAV replication during coinfection with AdV, which counteracts this effect by inactivating the complex. Here, we demonstrate that MRN positively regulates AAV replication during coinfection with HSV-1. Importantly, our study also indicates that MRN also favors integration of AAV genomes within the human AAVS1 site. Altogether, this work indicates that MRN differentially regulates AAV replication depending on the helper virus which is present and identifies a new function of this DNA repair complex during AAV integration.
Collapse
Affiliation(s)
- Rachel Millet
- International Center for Research in Infectiology, INSERM U1111, CNRS UMR5308, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université de Lyon, UCB-Lyon 1, Lyon, France LabEx Ecofect, Université de Lyon, Lyon, France
| | - Nelly Jolinon
- International Center for Research in Infectiology, INSERM U1111, CNRS UMR5308, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université de Lyon, UCB-Lyon 1, Lyon, France
| | - Xuan-Nhi Nguyen
- International Center for Research in Infectiology, INSERM U1111, CNRS UMR5308, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université de Lyon, UCB-Lyon 1, Lyon, France LabEx Ecofect, Université de Lyon, Lyon, France
| | - Gregory Berger
- International Center for Research in Infectiology, INSERM U1111, CNRS UMR5308, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université de Lyon, UCB-Lyon 1, Lyon, France
| | - Andrea Cimarelli
- International Center for Research in Infectiology, INSERM U1111, CNRS UMR5308, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université de Lyon, UCB-Lyon 1, Lyon, France LabEx Ecofect, Université de Lyon, Lyon, France
| | - Anna Greco
- International Center for Research in Infectiology, INSERM U1111, CNRS UMR5308, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université de Lyon, UCB-Lyon 1, Lyon, France LabEx Ecofect, Université de Lyon, Lyon, France
| | - Pascale Bertrand
- INSERM U967, CEA, Université Paris Diderot, Université Paris Sud, CEA DSV, Institut de Radiobiologie Moléculaire et Cellulaire, Fontenay-aux-Roses, France
| | - Margarete Odenthal
- Institute for Pathology, University Hospital of Cologne, Cologne, Germany Center for Molecular Medicine of Cologne, University of Cologne, Cologne, Germany
| | - Hildegard Büning
- Center for Molecular Medicine of Cologne, University of Cologne, Cologne, Germany Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany German Center for Infection Research, Bonn-Cologne Partner Site, Bonn-Cologne, Germany
| | - Anna Salvetti
- International Center for Research in Infectiology, INSERM U1111, CNRS UMR5308, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université de Lyon, UCB-Lyon 1, Lyon, France LabEx Ecofect, Université de Lyon, Lyon, France
| |
Collapse
|